MedPath

24hrs skin sensitivity patch test on healthy human volunteers.

Completed
Conditions
Sensitive skin type
Registration Number
CTRI/2016/07/007064
Lead Sponsor
ITC Life Science and Technology Centre
Brief Summary

Objective:

The Objective of the study is to evaluate the dermatological safety of investigational products on healthy human subjects

Subject Population:

24 healthy human volunteers (Male and Female 1:1) with skin type 1:1:1:1 ratio ( Oily,Dry,Normal and Combination)

Duration of study:

Approximately 9 days for each volunteer

The patch will be applied at the test site of study subjects starting with the lower edge of the patch system and slowly pressing upwards till the top edge in order to squeeze out the air.

This patch will then be applied on the test site i.e. between the scapulae and waist of the subjects. The patch will be kept for 24 hours. After which the patches will be removed and the first observation will be made at 30 minutes of patch removal (0 hr. observation). The further observations will be at 24 hr and 1 week of patch

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
24
Inclusion Criteria
  • •Subjects in the age group 18.
  • 55 years (both the ages inclusive). •Healthy male & female subjects. •Subjects with Fitzpatrick skin type III to V. •Subjects willing to give a written informed consent. •Subjects willing to maintain the patch test in position for 24 hours. •Subject having not participated in a similar investigation in the past two weeks. •Subjects willing to come for regular follow up visits. •Subjects ready to follow instructions during the study period.
Exclusion Criteria
  • •Infection, allergy on the tested area.
  • •Skin allergy antecedents or atopic subjects.
  • •Athletes and subjects with history of excessive sweating.
  • •Cutaneous disease which may influence the study result.
  • •Subjects on oral corticosteroid.
  • •Subjects participating in any other cosmetic or therapeutic study.
  • •Any history of underlying uncontrolled medical illness including diabetes, liver disease or history of alcoholism, HIV or any other serious medical illness.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To evaluate the dermatological safety of the investigational products on healthy human subjects0hr,24hr and 7days post patch removal
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

MS Clinical research Pvt.Ltd.

🇮🇳

Bangalore, KARNATAKA, India

MS Clinical research Pvt.Ltd.
🇮🇳Bangalore, KARNATAKA, India
DrSapnaR
Principal investigator
08041125934
sapna.r@mscr.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.